Spain's Idifarma adds capsule filling to service offerings

By Dan Stanton

- Last updated on GMT

Image: iStock/jgaunion
Image: iStock/jgaunion

Related tags Investment

Idifarma has invested over €300,000 in its facility in Spain in order to offer its customers automated capsule filling for commercial batches.

The Spanish contract development and manufacturing organisation (CDMO) has bought a Bosch GKF-702 capsule filling machine and is planning to add new rooms and capacity at its site in Pamplona as part of an investment exceeding €300,000 ($320,000).

“We are currently not offering automated capsule filling, so this will be a relevant addition to our service offering since we will start providing contract manufacturing services in capsules,” ​director of business development Manuel Leal Sanchez told in-Pharmatechnologist.com.

“We have extensive experience developing projects for clients in hard capsules, and we have also manufactured many small batches for clinical trials so far, but this new equipment will start bringing commercial manufacturing opportunities.”

Once installed and approved – expected early 2017 – the site will be capable of manufacturing up to 42,000 capsules per hour.

The investment has not been made to service a specific client but for “strategic reasons,”​ Leal Sanchez said.

“It is not project-specific, but we already have some ongoing products under development that we will be able to manufacture commercially for our clients with this new equipment.”

Increasing manufacturing focus

Earlier this year​, API maker Suanfarma acquired a stake in Idifarma, providing the Spanish CDMO with greater access to non-European markets. Suanfarma has a presence in the US, India, China, Brazil and Mexico.

With this and the new investment, Leal Sanchez said his firm hoped to continue to grow its manufacturing presence and services globally over the next few years.

“Our plan is to keep serving and growing our client base as we invest in other technologies for development and manufacturing,”​ he said.

“Our business model as a CDO [contract development organisation] is solid and we have a great track record over our 15 years of history. The CMO part of our business is more recent and growing rapidly thanks to our focused and niche approach to contract manufacturing and our high potency capabilities.”

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us

Products

View more

Webinars